These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 24069472)

  • 21. The use of steroids to prevent cutaneous reactions to benznidazole in patients with Chagas disease.
    Górgolas M; Robles I; Cabello A; Pérez-Tanoira R; Peremarch CP; Fernández-Roblas R; Williams F; Rincón JM
    Pathog Glob Health; 2013 Apr; 107(3):157-60. PubMed ID: 23683371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunosuppression and Chagas disease; experience from a non-endemic country.
    Salvador F; Sánchez-Montalvá A; Valerio L; Serre N; Roure S; Treviño B; Pou D; Sulleiro E; Bocanegra C; Molina I
    Clin Microbiol Infect; 2015 Sep; 21(9):854-60. PubMed ID: 26055418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toxic Profile of Benznidazole in Patients with Chronic Chagas Disease: Risk Factors and Comparison of the Product from Two Different Manufacturers.
    Molina I; Salvador F; Sánchez-Montalvá A; Treviño B; Serre N; Sao Avilés A; Almirante B
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6125-31. PubMed ID: 26195525
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of cytokine profile and HLA association in benznidazole related cutaneous reactions in patients with Chagas disease.
    Salvador F; Sánchez-Montalvá A; Martínez-Gallo M; Sala-Cunill A; Viñas L; García-Prat M; Aparicio G; Sao Avilés A; Artaza MÁ; Ferrer B; Molina I
    Clin Infect Dis; 2015 Dec; 61(11):1688-94. PubMed ID: 26265500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nifurtimox therapy for Chagas disease does not cause hypersensitivity reactions in patients with such previous adverse reactions during benznidazole treatment.
    Pérez-Molina JA; Sojo-Dorado J; Norman F; Monge-Maillo B; Díaz-Menéndez M; Albajar-Viñas P; López-Vélez R
    Acta Trop; 2013 Aug; 127(2):101-4. PubMed ID: 23583863
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Arthritis and benznidazole: more closely related than we thought.
    Aldasoro E; Pinazo MJ; Oliveira I; Munoz J; Posada E; Requena-Méndez A; Serret N; Gascon J
    Antimicrob Agents Chemother; 2015 Jan; 59(1):727-9. PubMed ID: 25385100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessing antibody decline after chemotherapy of early chronic Chagas disease patients.
    Murphy N; Cardinal MV; Bhattacharyya T; Enriquez GF; Macchiaverna NP; Alvedro A; Freilij H; Martinez de Salazar P; Molina I; Mertens P; Gilleman Q; Gürtler RE; Miles MA
    Parasit Vectors; 2021 Oct; 14(1):543. PubMed ID: 34670602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of HLA-B∗35 and moderate or severe cutaneous reactions secondary to benznidazole treatment in chronic chagas disease.
    Bosch-Nicolau P; Salvador F; Sánchez-Montalvá A; Franco-Jarava C; Arrese-Muñoz I; Sulleiro E; Roure S; Valerio L; Oliveira-Souto I; Serre-Delcor N; Pou D; Treviño B; Aznar ML; Espinosa-Pereiro J; Molina I
    Clin Microbiol Infect; 2022 Jun; 28(6):881.e1-881.e5. PubMed ID: 34863919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High frequency of adverse reactions and discontinuation with benznidazole treatment for chronic Chagas disease in Milan, Italy.
    Antinori S; Grande R; Bianco R; Traversi L; Cogliati C; Torzillo D; Repetto E; Corbellino M; Milazzo L; Galli M; Galimberti L
    Clin Infect Dis; 2015 Jun; 60(12):1873-5. PubMed ID: 25805302
    [No Abstract]   [Full Text] [Related]  

  • 30. Achievements and challenges upon the implementation of a program for national control of congenital Chagas in Bolivia: results 2004-2009.
    Alonso-Vega C; Billot C; Torrico F
    PLoS Negl Trop Dis; 2013; 7(7):e2304. PubMed ID: 23875039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low Incidence of Adverse Effects Using a Progressive Regimen of Benznidazole in Chagas Disease.
    Navarrete MN; Gutiérrez-Gutiérrez B; de Arellano-Ramos R; Del Castillo SF; Domínguez-Castellano Á
    Clin Infect Dis; 2016 Apr; 62(8):1052. PubMed ID: 26769725
    [No Abstract]   [Full Text] [Related]  

  • 32. Adverse events after the use of benznidazole in infants and children with Chagas disease.
    Altcheh J; Moscatelli G; Moroni S; Garcia-Bournissen F; Freilij H
    Pediatrics; 2011 Jan; 127(1):e212-8. PubMed ID: 21173000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Longitudinal follow up of serological response in children treated for Chagas disease.
    Moscatelli G; Moroni S; García Bournissen F; González N; Ballering G; Schijman A; Corral R; Bisio M; Freilij H; Altcheh J
    PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007668. PubMed ID: 31465522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse systemic reaction to benznidazole.
    Coronel MV; Frutos LO; Muñoz EC; Valle DK; Rojas DH
    Rev Soc Bras Med Trop; 2017; 50(1):145-147. PubMed ID: 28327820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The epidemiology of adverse drug events and medication errors among psychiatric inpatients in Japan: the JADE study.
    Ayani N; Sakuma M; Morimoto T; Kikuchi T; Watanabe K; Narumoto J; Fukui K
    BMC Psychiatry; 2016 Aug; 16(1):303. PubMed ID: 27577925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety Profile of Benznidazole in the Treatment of Chronic Chagas Disease: Experience of a Referral Centre and Systematic Literature Review with Meta-Analysis.
    Crespillo-Andújar C; Venanzi-Rullo E; López-Vélez R; Monge-Maillo B; Norman F; López-Polín A; Pérez-Molina JA
    Drug Saf; 2018 Nov; 41(11):1035-1048. PubMed ID: 30006773
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease.
    Molina I; Gómez i Prat J; Salvador F; Treviño B; Sulleiro E; Serre N; Pou D; Roure S; Cabezos J; Valerio L; Blanco-Grau A; Sánchez-Montalvá A; Vidal X; Pahissa A
    N Engl J Med; 2014 May; 370(20):1899-908. PubMed ID: 24827034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adults.
    Altcheh J; Moscatelli G; Mastrantonio G; Moroni S; Giglio N; Marson ME; Ballering G; Bisio M; Koren G; García-Bournissen F
    PLoS Negl Trop Dis; 2014 May; 8(5):e2907. PubMed ID: 24853169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Adverse reactions in Chagas disease patients treated with benznidazole, in the State of Ceará].
    de Pontes VM; Souza Júnior AS; Cruz FM; Coelho HL; Dias AT; Coêlho IC; Oliveira Mde F
    Rev Soc Bras Med Trop; 2010; 43(2):182-7. PubMed ID: 20464150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection).
    Vallejo M; Reyes PP; Martinez Garcia M; Gonzalez Garay AG
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD004102. PubMed ID: 33305846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.